Aging With HIV and Neurocognitive Decline, a Follow-up Study

The primary objective of this study is to analyze whether PLHIV initially aged between 55-70 years of age at baseline under antiretroviral therapy have accelerated decline of neurocognitive function after 6 years of follow-up in comparison with an age, gender and educational level matched HIV non-exposed control group from the CONSTANCES cohort.

The secondary objectives of this study are :

• To determine the prevalence of neurocognitive impairment (NCI) according to the Frascati criteria, clinical consensus and alternative classifications, after additional accrual of individuals aged 55 to 76 years for a more precise and extensive age range analysis of NCI
• To describe the incidence and prevalence of the frailty syndromes, and their relation with co-morbidities and NCI, using the Fried score as a measure of frailty
• To constitute a plasma and serum biobank for biomarkers study related to the aging of PLHIV

Inclusion criteria

Inclusion criteria

for PLHIV for the longitudinal study:

• Having participated in the ANRS EP58 HAND 55-70 study
• A signed informed consent
• To be affiliated and benefit from the French Social Security

Inclusion criteria

for PLHIV for the transversal study (only for new subjects):

• HIV-1
• Aged between 55 years and 76 years;
• with a viral load < 50 copies/mL for more than 24 months (with a minimum of 3 available viral loads 6 months prior to inclusion). Blips -defined by a transient increase in viral load- are allowed if < 200 copies/mL, with a maximum of two blips within 24 months;
• With a CD4 (cluster of differentiation 4) count at inclusion ≥ 200 cells/µL for more than the last 12 months (with a last available CD4 count < 6 months of inclusion);
• A signed informed consent
• To be affiliated and benefit from the French Social Security

Exclusion criteria

Non-inclusion criteria for PLHIV for both the longitudinal and transversal studies:

• An Isolated HIV-2 infection
• Confused or with an ongoing neurological disease
• Presenting psychiatric syndromes interfering with cognitive evaluation;
• With sensorial loss, analphabetism or language barriers rendering the interpretation of tests difficult.
• With recent extensive neurocognitive evaluation within 6 months prior to inclusion
• With neurological disease with ongoing clinically relevant sequela
• Participating in another research program, prohibiting the participating in additional research
• Vulnerable: minors, under guardianship or curatorship, or persons deprived of liberty for administrative or judiciary reasons